Immune thrombocytopeniaNews & Research
15 curated articles for Immune thrombocytopenia — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Research and practice in thrombosis and haemostasis Apr 22, 2026
The association between immature platelet count and clinical characteristics in pediatric immune thrombocytopenia.
Despite the increasing number of treatments for immune thrombocytopenia (ITP), there are no established laboratory predictors of treatment response. Immature platelet fraction (IPF) and immature platelet count (IPC) are clinical laboratory measurements reflecting bone marrow thrombopoietic activity....
Why it matters: Recent peer-reviewed research on Immune thrombocytopenia that may be relevant for patients and caregivers.
- Cureus Apr 22, 2026
Clinical Characteristics and Predictors of Chronicity in Children With Immune Thrombocytopenia.
Introduction Immune thrombocytopenia (ITP) in children is typically self-limited; however, a subset progresses to chronic disease. Identifying early predictors of chronic evolution remains clinically important to improve risk stratification and management strategies. Methods We conducted a retrospec...
Why it matters: Recent peer-reviewed research on Immune thrombocytopenia that may be relevant for patients and caregivers.
- The New England journal of medicine Apr 15, 2026
Ianalumab plus Eltrombopag in Immune Thrombocytopenia.
Current second-line treatments for immune thrombocytopenia (ITP) require long-term administration. Ianalumab, a monoclonal antibody targeting B cells, is being assessed as a short-course second-line therapy in ITP. In this phase 3, randomized, double-blind trial, we assigned, in a 1:1:1 ratio, adult...
Why it matters: Recent peer-reviewed research on Immune thrombocytopenia that may be relevant for patients and caregivers.
- British journal of haematology Apr 9, 2026
Thrombosis in immune thrombocytopenia.
Patients with immune thrombocytopenia (ITP) have a higher thrombotic rate than the general population, and certain ITP treatments may further increase this risk. This narrative 'In a Nutshell' review provides an overview on thrombosis in adults with primary ITP and the haemostatic changes contributi...
Why it matters: Recent peer-reviewed research on Immune thrombocytopenia that may be relevant for patients and caregivers.
- Blood reviews Apr 8, 2026
The humoral pathophysiology of immune thrombocytopenia: How close are we to patient-specific disease treatment?
Primary immune thrombocytopenia (ITP) is an autoimmune disease in which soluble humoral immune factors, especially anti-platelet autoantibodies, can drive thrombocytopenia by accelerating platelet clearance and impairing platelet production. The classical humoral mechanisms of ITP include autoantibo...
Why it matters: Recent peer-reviewed research on Immune thrombocytopenia that may be relevant for patients and caregivers.
- Journal of clinical medicine Mar 28, 2026
Navigating the Hemostatic Balance: Anticoagulation and Antiplatelet Therapy in Patients with Thrombocytopenia.
Background: Thrombocytopenia is traditionally perceived as a bleeding-predominant condition; however, growing evidence indicates that many thrombocytopenic states are paradoxically associated with an increased risk of venous and arterial thrombosis. This dual hemostatic derangement poses major thera...
Why it matters: Recent peer-reviewed research on Immune thrombocytopenia that may be relevant for patients and caregivers.
- Research and practice in thrombosis and haemostasis Mar 20, 2026
The glycan fingerprint in immune thrombocytopenia.
A state-of-the-art lecture titled "Platelet Glycobiology and Immune Thrombocytopenia (ITP)" was presented at the International Society on Thrombosis and Haemostasis (ISTH) congress in 2025. In this review, we summarize the current knowledge on glycan-mediated mechanisms in ITP, including glycan alte...
Why it matters: Recent peer-reviewed research on Immune thrombocytopenia that may be relevant for patients and caregivers.
- Journal of chemotherapy (Florence, Italy) Mar 20, 2026
Pembrolizumab associated immune thrombocytopenia.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but are associated with immune-related adverse events (irAEs). Pembrolizumab, an anti-PD-1 antibody, is widely used in non-small cell lung cancer (NSCLC), yet immune thrombocytopenia remains a rare but potentially fatal complic...
Why it matters: Recent peer-reviewed research on Immune thrombocytopenia that may be relevant for patients and caregivers.
- Blood Mar 19, 2026
Immune thrombocytopenia in patients treated with immune checkpoint inhibitors.
Immune checkpoint inhibitor-associated immune thrombocytopenia (ICI-ITP) has been described in case reports and small case series, but comprehensive data on its incidence, risk factors, clinical features, treatment, and outcomes are lacking. We reviewed medical records of all adults initiating ICI t...
Why it matters: Recent peer-reviewed research on Immune thrombocytopenia that may be relevant for patients and caregivers.
- Drugs Mar 7, 2026
Rilzabrutinib: First Approval.
Rilzabrutinib (WAYRILZ™) is a small-molecule, reversible, highly specific, covalent BTK inhibitor being developed by Sanofi for the treatment of multiple immune-related and inflammatory disorders, including immune thrombocytopenia, warm autoimmune haemolytic anaemia, sickle cell disease, IgG4...
Why it matters: Recent peer-reviewed research on Immune thrombocytopenia that may be relevant for patients and caregivers.
- Journal of thrombosis and haemostasis : JTH Mar 4, 2026
Immunopathology of immune thrombocytopenia.
Immune thrombocytopenia (ITP) is an acquired bleeding disorder caused by complex immune dysregulation. ITP is a rare disorder with significant morbidity; patients experience bleeding symptoms and reduced quality of life. The pathogenesis of ITP can be observed at several levels: the mechanisms of th...
Why it matters: Recent peer-reviewed research on Immune thrombocytopenia that may be relevant for patients and caregivers.
- The New England journal of medicine Mar 4, 2026
Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome.
Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome.
Why it matters: Recent peer-reviewed research on Immune thrombocytopenia that may be relevant for patients and caregivers.
- The New England journal of medicine Feb 11, 2026
Adenoviral Inciting Antigen and Somatic Hypermutation in VITT.
Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare prothrombotic complication that occurs after adenoviral vector-based vaccination against coronavirus disease 2019; in rare cases, it can also occur after natural adenovirus infection. VITT is mediated by platelet-activating anti...
Why it matters: Recent peer-reviewed research on Immune thrombocytopenia that may be relevant for patients and caregivers.
- The American journal of managed care Jan 28, 2026
Immune thrombocytopenia: contemporary pathophysiology, treatment gaps, and the role of novel mechanisms in patient-centered care.
Immune thrombocytopenia (ITP) is a chronic autoimmune disorder associated with platelet destruction and increased bleeding risk, substantial economic burden, and impairment of health-related quality of life. The pathophysiology of ITP involves increased platelet destruction and impaired platelet pro...
Why it matters: Recent peer-reviewed research on Immune thrombocytopenia that may be relevant for patients and caregivers.
- American journal of hematology Jan 5, 2026
Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial.
Iptacopan is a first-in-class, oral, selective inhibitor of complement factor B that has demonstrated positive efficacy across several complement-driven diseases. Here we evaluate the efficacy and safety of iptacopan monotherapy in adult patients with primary immune thrombocytopenia (ITP) and primar...
Why it matters: Recent peer-reviewed research on Immune thrombocytopenia that may be relevant for patients and caregivers.
More on Immune thrombocytopenia
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.